3,26-Dihydroxycholest-5-ene-16,22-dione | 468-99-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3,26-Dihydroxycholest-5-ene-16,22-dione
• 英文别名: 3-hydroxy-17-(7-hydroxy-6-methyl-3-oxoheptan-2-yl)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,17-dodecahydrocyclopenta[a]phenanthren-16-one
• CAS: 468-99-5；64161-55-3
• 化学式: C₂₇H₄₂O₄
• 分子量: 430.6
• InChiKey: GDKGOXUWEBGZBY-UHFFFAOYSA-N

物化性质

• 熔点：
  187-189 °C
• 沸点：
  597.0±50.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,26-Dihydroxycholest-5-ene-16,22-dione 、 甲胺 生成 6-(4-hydroxy-3-methylbutyl)-5,7,9,13-tetramethyl-5-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-4(8),6,18-trien-16-ol
  参考文献：
  名称：

  MOFFETT R. B., J. CHEM. AND ENG. DATA, 1980, 25, NO 2, 176-183

  摘要：

  DOI：

文献信息

• Preparation of prodrugs for selective drug delivery
  申请人：Mills L. Randell

  公开号：US20050080260A1

  公开（公告）日：2005-04-14

  Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

  合成具有A-B-C化学式的化合物，可用于药物传递等应用，其中A是化学发光基团，B是光致变色基团，C是生物活性基团，其中A-B-C可作为前药。本发明的新型合成方法用于形成前药，包括以下步骤：(1)形成苯酮，(2)形成二芳基乙烯，(3)将邻苯二甲酰亚胺基团连接到乙烯的至少一个芳基上，形成邻苯二甲酰亚胺-乙烯共轭物，(4)缩合两个乙烯-邻苯二甲酰亚胺共轭物，形成邻苯二甲酰亚胺-戊二烯共轭物，(5)通过与肼反应将邻苯二甲酰亚胺转化为邻苯二酰肼，形成本发明的载体化合物，(6)将载体化合物与药物的亲核基团反应，形成相应的前药。另外，可以通过使用卤代二芳基乙烯制备相应的阳离子类似的类似类似染料化合物。然后，通过与亲核试剂反应保护阳离子类似化合物，并通过钯催化的胺化与氨基邻苯二甲酰亚胺偶联，形成保护的邻苯二甲酰亚胺-戊二烯共轭物。后者与肼回流，将其邻苯二甲酰亚胺转化为邻苯二酰肼，并酸化以得到载体。本发明的另一个方面涉及将这些化合物用作抗病毒剂，用于治疗病毒感染，如HIV，以及用作抗癌剂，用于治疗结肠癌、肺癌和乳腺癌等癌症。
• Steroidal sapogenins for the control of coccidiosis in animals
  申请人：Distributors Processing Inc.

  公开号：EP1082909A1

  公开（公告）日：2001-03-14

  This invention relates to a pharmaceutical composition having anticoccidial activity comprising of steroidal sapogenins, which can be added to animal feeds or water to control diseases caused by coccidian Eimeria.

  本发明涉及一种具有抗球虫活性的药物组合物，它由甾体苷元组成，可添加到动物饲料或水中，以控制由球虫艾美耳菌引起的疾病。
• Use of core 2 GlcNac-T inhibitors III for treating autoimmune diseases
  申请人：BTG International Limited

  公开号：EP2382979A2

  公开（公告）日：2011-11-02

  Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R1 is H, -OH, C1-6 alkoxy, -NR5R6, or Sac 1; R2 is H, -OH, C1-6 alkoxy or Sac 2; R3 is H, -OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof, wherein the condition is an autoimmune condition.

  使用式 I 的化合物可治疗涉及核心 2 GlcNAc - T 酶有害活性的病症。 其中 R1 是 H、-OH、C1-6 烷氧基、-NR5R6 或 Sac 1； R2 是 H、-OH、C1-6 烷氧基或 Sac 2； R3 是 H、-OH、C1-6 烷氧基或 Sac 3； R4 是 H、C1-6-烷基、C1-6-羟基烷基或 C1-6- 烷氧基-C1-6-烷基； R5 是 H、C1-6 烷基或 C1-6酰基； R6 是 H、C1-6 烷基或 C1-6 丙烯酸基； Sac 1 Sac 2 和 Sac 3 是独立选定的糖分子；以及 Z 是类固醇分子； 或其药学上可接受的盐、醚或酯形式，其中所述病症为自身免疫性病症。
• Use of Core 2 GlcNac-T inhibitors III for treating vascular complications of diabetes
  申请人：BTG International Limited

  公开号：EP2382980A2

  公开（公告）日：2011-11-02

  Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R1 is H, -OH, C1-6 alkoxy, -NR5R6, or Sac 1; R2 is H, -OH, C1-6 alkoxy or Sac 2; R3 is H, -OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof, wherein the condition is selected from vascular complications of diabetes.

  使用式 I 的化合物可治疗涉及核心 2 GlcNAc - T 酶有害活性的病症。 其中 R1 是 H、-OH、C1-6 烷氧基、-NR5R6 或 Sac 1； R2 是 H、-OH、C1-6 烷氧基或 Sac 2； R3 是 H、-OH、C1-6 烷氧基或 Sac 3； R4 是 H、C1-6-烷基、C1-6-羟基烷基或 C1-6- 烷氧基-C1-6-烷基； R5 是 H、C1-6 烷基或 C1-6酰基； R6 是 H、C1-6 烷基或 C1-6 丙烯酸基； Sac 1 Sac 2 和 Sac 3 是独立选定的糖分子；以及 Z 是类固醇分子； 或其药学上可接受的盐、醚或酯形式，其中所述病症选自糖尿病的血管并发症。
• Use of Core 2 GlcNac-T inhibitors III for the treatment of inflammatory conditions
  申请人：BTG International Limited

  公开号：EP2382981A2

  公开（公告）日：2011-11-02

  Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R1 is H, -OH, C1-6 alkoxy, -NR5R6, or Sac 1; R2 is H, -OH, C1-6 alkoxy or Sac 2; R3 is H, -OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof, wherein the condition to be treated is an inflammatory condition selected from ileitis, cholitis, cholecystitis, diverticulitis, gastritis, irritable bowel syndrome, inflammatory bowel disease, Lupus and ulcerative cholitis.

  使用式 I 的化合物可治疗涉及核心 2 GlcNAc - T 酶有害活性的病症。 其中 R1 是 H、-OH、C1-6 烷氧基、-NR5R6 或 Sac 1； R2 是 H、-OH、C1-6 烷氧基或 Sac 2； R3 是 H、-OH、C1-6 烷氧基或 Sac 3； R4 是 H、C1-6-烷基、C1-6-羟基烷基或 C1-6- 烷氧基-C1-6-烷基； R5 是 H、C1-6 烷基或 C1-6酰基； R6 是 H、C1-6 烷基或 C1-6 丙烯酸基； Sac 1 Sac 2 和 Sac 3 是独立选择的糖分子；以及 Z 是类固醇分子； 或其药学上可接受的盐、醚或酯形式，其中待治疗的病症是选自回肠炎、胆囊炎、胆囊炎、憩室炎、胃炎、肠易激综合征、炎症性肠病、红斑狼疮和溃疡性胆炎的炎症。